Trifluoperazine for schizophrenia
Trifluoperazine for schizophrenia is a topic covered in the Evidence-Based Medicine Guidelines.
To view the entire topic, please log in or purchase a subscription.
Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Explore these free sample topics:
There's more to see -- the rest of this topic is available only to subscribers.
"Trifluoperazine for Schizophrenia." Evidence-Based Medicine Guidelines, Duodecim Medical Publications Limited, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/456552/all/Trifluoperazine_for_schizophrenia.
Trifluoperazine for schizophrenia. Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. https://evidence.unboundmedicine.com/evidence/view/EBMG/456552/all/Trifluoperazine_for_schizophrenia. Accessed March 31, 2023.
Trifluoperazine for schizophrenia. (2019). In Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited. https://evidence.unboundmedicine.com/evidence/view/EBMG/456552/all/Trifluoperazine_for_schizophrenia
Trifluoperazine for Schizophrenia [Internet]. In: Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. [cited 2023 March 31]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/456552/all/Trifluoperazine_for_schizophrenia.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - Trifluoperazine for schizophrenia ID - 456552 BT - Evidence-Based Medicine Guidelines UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/456552/all/Trifluoperazine_for_schizophrenia PB - Duodecim Medical Publications Limited DB - Evidence Central DP - Unbound Medicine ER -